Details for Patent: 6,429,209
✉ Email this page to a colleague
Title: | Methods for treating irritable bowel syndrome |
Abstract: | This invention relates to the use of 5-HT3 receptor antagonists in the treatment of nonconstipated female IBS patients. |
Inventor(s): | Mangel; Allen Wayne (Chapel Hill, NC), Northcutt; Allison Ruth (Raleigh, NC) |
Assignee: | SmithKline Beecham Corporation (Philadelphia, PA) |
Filing Date: | Apr 13, 2001 |
Application Number: | 09/834,717 |
Claims: | 1. A method of treatment of pain associated with non-constipated female IBS which comprises administering an effective amount of a 5-HT.sub.3 receptor antagonist or a pharmaceutically acceptable derivative thereof. 2. A method of treatment according to claim 1, wherein the 5-HT.sub.3 receptor antagonist is alosetron or a pharmaceutically acceptable derivative thereof. 3. A method of treatment according to claim 2, wherein alosetron is in the form of its hydrochloride. 4. A method of treatment according to claim 1, wherein the 5-HT.sub.3 receptor antagonist is selected from granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, indisetron and dolasetron. 5. A method of improving stool consistency in a patient afflicted with non-constipated female IBS which comprises administering an effective amount of a 5-HT.sub.3 receptor antagonist or a pharmaceutically acceptable derivative thereof. 6. A method of treatment according to claim 5, wherein the 5-HT.sub.3 receptor antagonist is alosetron or a pharmaceutically acceptable derivative thereof. 7. A method of treatment according to claim 6, wherein alosetron is in the form of its hydrochloride. 8. A method of treatment according to claim 5, wherein the 5-HT.sub.3 receptor antagonist is selected from granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, indisetron and dolasetron. 9. A method of decreasing urgency in a subject afflicted with non-constipated female IBS which comprises administering an effective amount of a 5-HT.sub.3 receptor antagonist or a pharmaceutically acceptable derivative thereof. 10. A method of treatment according to claim 9, wherein the 5-HT.sub.3 receptor antagonist is alosetron or a pharmaceutically acceptable derivative thereof. 11. A method of treatment according to claim 10, wherein alosetron is in the form of its hydrochloride. 12. A method of treatment according to claim 9, wherein the 5-HT.sub.3 receptor antagonist is selected from granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, indisetron and dolasetron. |